Manipal Health

Manipal Health Enterprises Limited, part of the renowned Manipal Group founded by T. M. A. Pai, is a cornerstone of the Indian private healthcare landscape. The company has evolved into a multi-specialty healthcare provider, focusing on making high-quality medical care more accessible across its operational geographies.

Its business model is centered on a hub-and-spoke network of hospitals and clinics. The company offers a wide array of critical and preventive healthcare services, including organ transplants, cardiology, neurology, orthopaedics, and oncology, catering to a diverse patient base requiring both primary and tertiary care.

In terms of operational scale, as of September 30, 2025, the company operates 38 hospitals, which expands to 48 hospitals on a pro forma basis. This infrastructure supports a massive capacity of 10,761 beds, increasing to 12,367 licensed beds on a pro forma basis, complemented by 17 specialized clinics.

The company is led by a strong promoter group including Dr. Ranjan Ramdas Pai and various investment entities such as Memg International Ltd and Kabru Investments Pte. Ltd. Their strategic direction has shifted toward aggressive scaling and enhancing the clinical capabilities of their healthcare facilities to maintain a competitive market position.

The Manipal Health IPO is a massive book-build issue seeking to raise approximately ₹9,273.64 crores. The issue is structured with a heavy emphasis on growth, featuring a fresh issue of ₹7,998.43 crores and an offer for sale of 2,16,13,834 equity shares. The price band is set between ₹560 and ₹590 per share, with a minimum retail lot size of 25 shares amounting to ₹14,750. The IPO was open from July 29 to July 31, 2026, with listing on the BSE and NSE on August 5, 2026.

The proceeds from the fresh issue are primarily earmarked for debt reduction and strategic expansion. A significant portion, ₹5,378.00 crores, is allocated for the repayment or prepayment of borrowings of its material subsidiary, Manipal Hospitals Private Limited, while ₹574.00 crores will be used to acquire a minority stake in Sahyadri Hospitals Private Limited.

Financial performance shows a strong top-line trajectory, with revenue growing from ₹6,265.17 crores in 2024 to ₹10,520.52 crores in 2026. However, profitability has seen some volatility; PAT rose sharply to ₹1,081.67 crores in 2025 but dipped to ₹916.52 crores in 2026, suggesting a compression in margins or increased operational costs.

Valuation-wise, the company reports a basic EPS of ₹7.71 and an ROCE of 21.88%. While specific P/E ratios for the IPO are not explicitly detailed, comparisons with peers like Apollo Hospitals, Fortis, and Max Healthcare—who command high P/E multiples (66x to 74x)—indicate the sector's high valuation premium. A key strength is the massive scale and brand equity, while the primary risk is the sheer size of the issue, which may lead to listing day volatility due to the high float.